Biomarkers for early detection of ovarian cancer

Women's Health

Volumn 9, Issue 2, 2013, Pages 171-187

  Nguyen, Long ^a   Cardenas Goicoechea, Segundo Joel ^a   Gordon, Pierre ^b   Curtin, Christina ^a   Momeni, Mazdak ^a   Chuang, Linus ^a   Fishman, David ^a  

^a MOUNT SINAI MEDICAL CENTER   (United States)

^b HOWARD UNIVERSITY HOSPITAL   (United States)

Author keywords

biomarker; early detection; miRNA; ovarian cancer; proteomics

Indexed keywords

APOLIPOPROTEIN A1; BETA 2 MICROGLOBULIN; BRCA1 PROTEIN; BRCA2 PROTEIN; CA 125 ANTIGEN; COLONY STIMULATING FACTOR 1; EPIDERMAL GROWTH FACTOR RECEPTOR; GLYCOPROTEIN; HUMAN EPIDIDYMIS PROTEIN 4; INHIBIN; INTERLEUKIN 6; INTERLEUKIN 8; KALLIKREIN; KI 67 ANTIGEN; LYSOPHOSPHATIDIC ACID; MATRIX METALLOPROTEINASE; MESOTHELIN; MICRORNA; OSTEOPONTIN; OVX1 PROTEIN; PREALBUMIN; PROTEIN P53; SERUM AMYLOID A; TRANSFERRIN; TUMOR MARKER; UNCLASSIFIED DRUG; UROKINASE RECEPTOR; V SET DOMAIN CONTAINING T CELL ACTIVATION INHIBITOR 1; VASCULAR CELL ADHESION MOLECULE 1; VASCULOTROPIN;

CANCER SCREENING; CANCER STAGING; COLOR ULTRASOUND FLOWMETRY; DIAGNOSTIC ACCURACY; EARLY DIAGNOSIS; EXOSOME; FALSE POSITIVE RESULT; FAMILY HISTORY; FEMALE; GENE MUTATION; GENOMICS; HUMAN; IMMUNOHISTOCHEMISTRY; MASS SPECTROMETRY; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; MICROARRAY ANALYSIS; OVARY CANCER; PELVIC EXAMINATION; POLYMERASE CHAIN REACTION; PREDICTIVE VALUE; PROTEOMICS; REVIEW; RISK FACTOR; SENSITIVITY AND SPECIFICITY; TRANSVAGINAL ECHOGRAPHY; TUMOR SUPPRESSOR GENE;

BIOLOGICAL MARKERS; EARLY DETECTION OF CANCER; EDUCATION, CONTINUING; FEMALE; HUMANS; OVARIAN NEOPLASMS;

EID: 84874888546     PISSN: 17455057     EISSN: 17455065     Source Type: Journal    
DOI: 10.2217/whe.13.2     Document Type: Review

References (133)

1. Jelovac D, Armstrong DK. Recent progress in the diagnosis and treatment of ovarian cancer. CA Cancer J. Clin. 61(3), 183-203 (2011).
2. American Cancer Society. Global Cancer Fact & Figures 2011 (2nd Edition). American Cancer Society, Atlanta, GA, USA (2011).
3. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J. Clin. 61(2), 69-90 (2011).
4. Munoz KA, Harlan LC, Trimble EL. Patterns of care for women with ovarian cancer in the United States. J. Clin. Oncol. 15(11), 3408-3415 (1997).
5. Clarke-Pearson DL. Clinical practice. Screening for ovarian cancer. N. Engl. J. Med. 361(2), 170-177 (2009).
6. Buys SS, Partridge E, Black A et al. Effect of screening on ovarian cancer mortality: the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Randomized Controlled Trial. JAMA 305(22), 2295-2303 (2011).
7. Menon U, Kalsi J, Jacobs I. The UKCTOCS experience -reasons for hope? Int. J. Gynecol. Cancer 22(Suppl. 1), S18-S20 (2012).
8. Menon U, Gentry-Maharaj A, Hallett R et al. Sensitivity and specificity of multimodal and ultrasound screening for ovarian cancer, and stage distribution of detected cancers: results of the prevalence screen of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). Lancet Oncol. 10(4), 327-340 (2009).
9. American College of Obstetricians and Gynecologists Committee on Gynecologic Practice. Committee Opinion No. 477: the role of the obstetrician-gynecologist in the early detection of epithelial ovarian cancer. Obstetrics Gynecol. 117(3), 742-746 (2011).
10. Schorge JO, Modesitt SC, Coleman RL et al. SGO white paper on ovarian cancer: etiology, screening and surveillance. Gynecol. Oncol. 119(1), 7-17 (2010).
11. Rock JA, Jones HW, Te Linde RW. Te Linde's Operative Gynecology (10th Edition). Wolters Kluwer Health/Lippincott Williams & Wilkins, Philadelphia, PA, USA (2008).
12. Allain DC. Genetic counseling and testing for common hereditary breast cancer syndromes: a paper from the 2007 William Beaumont hospital symposium on molecular pathology. J. Mol. Diagn. 10(5), 383-395 (2008).
13. Pearce CL, Templeman C, Rossing MA et al. Association between endometriosis and risk of histological subtypes of ovarian cancer: a pooled analysis of case-control studies. Lancet Oncol. 13(4), 385-394 (2012).
14. Auersperg N, Wong AS, Choi KC, Kang SK, Leung PC. Ovarian surface epithelium: biology, endocrinology, and pathology. Endocr. Rev. 22(2), 255-288 (2001).
15. Crum CP. Intercepting pelvic cancer in the distal fallopian tube: theories and realities. Mol. Oncol. 3(2), 165-170 (2009).
16. Kindelberger DW, Lee Y, Miron A et al. Intraepithelial carcinoma of the fimbria and pelvic serous carcinoma: evidence for a causal relationship. Am. J. Surg. Pathol. 31(2), 161-169 (2007).
17. Visvanathan K, Vang R, Shaw P et al. Diagnosis of serous tubal intraepithelial carcinoma based on morphologic and immunohistochemical features: a reproducibility study. Am. J. Surg. Pathol. 35(12), 1766-1775 (2011).
18. Danforth KN, Tworoger SS, Hecht JL, Rosner BA, Colditz GA, Hankinson SE. Breastfeeding and risk of ovarian cancer in two prospective cohorts. Cancer Causes Control 18(5), 517-523 (2007).
19. Hankinson SE, Colditz GA, Hunter DJ et al. A prospective study of reproductive factors and risk of epithelial ovarian cancer. Cancer 76(2), 284-290 (1995).
20. Whittemore AS, Harris R, Itnyre J. Characteristics relating to ovarian cancer risk: collaborative analysis of 12 US case-control studies. II. Invasive epithelial ovarian cancers in white women. Collaborative Ovarian Cancer Group. Am. J. Epidemiol. 136(10), 1184-1203 (1992).
21. Rossing MA, Wicklund KG, Cushing-Haugen KL, Weiss NS. Predictive value of symptoms for early detection of ovarian cancer. J. Natl Cancer Inst. 102(4), 222-229 (2010).
22. Goff BA, Matthews BJ, Larson EH et al. Predictors of comprehensive surgical treatment in patients with ovarian cancer. Cancer 109(10), 2031-2042 (2007).
23. Cragun JM. Screening for ovarian cancer. Cancer Control 18(1), 16-21 (2011).
24. Myers ER, Bastian LA, Havrilesky LJ et al. Management of adnexal mass. Evid. Rep. Technol. Assess. (Full Rep.) (130), 1-145 (2006).
25. Fishman DA, Cohen L, Blank SV et al. The role of ultrasound evaluation in the detection of early-stage epithelial ovarian cancer. Am. J. Obstet. Gynecol. 192(4), 1214-1221; discussion 1221-1212 (2005).
26. Van Nagell JR Jr, Miller RW, Desimone CP et al. Long-term survival of women with epithelial ovarian cancer detected by ultrasonographic screening. Obstet. Gynecol. 118(6), 1212-1221 (2011).
27. Jacobs I, Menon U. Can ovarian cancer screening save lives? The question remains unanswered. Obstet. Gynecol. 118(6), 1209-1211 (2011).
28. Kupesic S, Kurjak A. Contrast-enhanced, three-dimensional power Doppler sonography for differentiation of adnexal masses. Obstet. Gynecol. 96(3), 452-458 (2000).
29. Marret H, Sauget S, Giraudeau B et al. Contrast-enhanced sonography helps in discrimination of benign from malignant adnexal masses. J. Ultrasound Med. 23(12), 1629-1639; quiz 1641-1642 (2004).
30. Fleischer AC, Lyshchik A, Jones HW 3rd et al. Diagnostic parameters to differentiate benign from malignant ovarian masses with contrast-enhanced transvaginal sonography. J. Ultrasound Med. 28(10), 1273-1280 (2009).
31. Bast RC Jr, Klug TL, St John E et al. A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. N. Engl. J. Med. 309(15), 883-887 (1983).
32. American College of Obstetricians and Gynecologists. PROLOG Gynecology and Surgery (6th Edition). American College of Obstetricians and Gynecologists, Washington, DC, USA (2009).
33. Skates SJ, Mai P, Horick NK et al. Large prospective study of ovarian cancer screening in high-risk women: CA125 cut-point defined by menopausal status. Cancer Prev. Res. (Phila.) 4(9), 1401-1408 (2011).
34. Drapkin R, Von Horsten HH, Lin Y et al. Human epididymis protein 4 (HE4) is a secreted glycoprotein that is overexpressed by serous and endometrioid ovarian carcinomas. Cancer Res. 65(6), 2162-2169 (2005).
35. Obeidat BR, Amarin ZO, Latimer JA, Crawford RA. Risk of malignancy index in the preoperative evaluation of pelvic masses. Int. J. Gynaecol. Obstet. 85(3), 255-258 (2004).
36. Galgano MT, Hampton GM, Frierson HF Jr. Comprehensive analysis of HE4 expression in normal and malignant human tissues. Mod. Pathol. 19(6), 847-853 (2006).
37. Lu KH, Patterson AP, Wang L et al. Selection of potential markers for epithelial ovarian cancer with gene expression arrays and recursive descent partition analysis. Clin. Cancer Res. 10(10), 3291-3300 (2004).
38. Hough CD, Sherman-Baust CA, Pizer ES et al. Large-scale serial analysis of gene expression reveals genes differentially expressed in ovarian cancer. Cancer Res. 60(22), 6281-6287 (2000).
39. Moore RG, Brown AK, Miller MC et al. The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass. Gynecol. Oncol. 108(2), 402-408 (2008).
40. Moore RG, Miller MC, Disilvestro P et al. Evaluation of the diagnostic accuracy of the risk of ovarian malignancy algorithm in women with a pelvic mass. Obstet. Gynecol. 118(2 Pt 1), 280-288 (2011).
41. Huhtinen K, Suvitie P, Hiissa J et al. Serum HE4 concentration differentiates malignant ovarian tumours from ovarian endometriotic cysts. Br. J. Cancer 100(8), 1315-1319 (2009).
42. Wu L, Dai ZY, Qian YH, Shi Y, Liu FJ, Yang C. Diagnostic value of serum human epididymis protein 4 (HE4) in ovarian carcinoma: a systematic review and metaanalysis. Int. J. Gynecol. Cancer 22(7), 1106-1112 (2012).
43. Yu S, Yang HJ, Xie SQ, Bao YX. Diagnostic value of HE4 for ovarian cancer: a meta-analysis. Clin. Chem. Lab. Med. 50(8), 1439-1446 (2012).
44. Moore RG, McMeekin DS, Brown AK et al. A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass. Gynecologic Oncol. 112(1), 40-46 (2009).
45. Jacob F, Meier M, Caduff R et al. No benefit from combining HE4 and CA125 as ovarian tumor markers in a clinical setting. Gynecol. Oncol. 121(3), 487-491 (2011).
46. Moore RG, Miller MC, Steinhoff MM et al. Serum HE4 levels are less frequently elevated than CA125 in women with benign gynecologic disorders. Am. J. Obstet. Gynecol. 206(4), 351.e1-8 (2012).
47. Mcintosh MW, Drescher C, Karlan B et al. Combining CA 125 and SMR serum markers for diagnosis and early detection of ovarian carcinoma. Gynecol. Oncol. 95(1), 9-15 (2004).
48. Obulhasim G, Fujii H, Matsumoto T et al. Mesothelin gene expression and promoter methylation/hypomethylation in gynecological tumors. Eur. J. Gynaecol. Oncol. 31(1), 63-71 (2010).
49. Tang Z, Qian M, Ho M. The role of mesothelin in tumor progression and targeted therapy. Anticancer Agents Med. Chem. doi:10.2174/1871520611313020014 (2012) (Epub ahead of print).
50. Badgwell D, Lu Z, Cole L et al. Urinary mesothelin provides greater sensitivity for early stage ovarian cancer than serum mesothelin, urinary hCG free beta subunit and urinary hCG beta core fragment. Gynecol. Oncol. 106(3), 490-497 (2007).
51. Schweigert FJ, Sehouli J. Transthyretin, a biomarker for nutritional status and ovarian cancer. Cancer Res. 65(3), 1114; author reply 1114 (2005).
52. Schweigert FJ, Wirth K, Raila J. Characterization of the microheterogeneity of transthyretin in plasma and urine using SELDI-TOF-MS immunoassay. Proteome Sci. 2(1), 5 (2004).
53. Mahlck CG, Grankvist K. Plasma prealbumin in women with epithelial ovarian carcinoma. Gynecol. Obstet. Invest. 37(2), 135-140 (1994).
54. Nosov V, Su F, Amneus M et al. Validation of serum biomarkers for detection of early-stage ovarian cancer. Am. J. Obstet. Gynecol. 200(6), 639 e1-e5 (2009).
55. Gadomska H, Grzechocinska B, Janecki J, Nowicka G, Powolny M, Marianowski L. Serum lipids concentration in women with benign and malignant ovarian tumours. Eur. J. Obstet. Gynecol. Reprod. Biol. 120(1), 87-90 (2005).
56. Su F, Kozak KR, Imaizumi S et al. Apolipoprotein A-I (apoA-I) and apoA-I mimetic peptides inhibit tumor development in a mouse model of ovarian cancer. Proc. Natl Acad. Sci. USA 107(46), 19997-20002 (2010).
57. Kim YW, Bae SM, Lim H, Kim YJ, Ahn WS. Development of multiplexed beadbased immunoassays for the detection of early stage ovarian cancer using a combination of serum biomarkers. PloS ONE 7(9), e44960 (2012).
58. Slack-Davis JK, Atkins KA, Harrer C, Hershey ED, Conaway M. Vascular cell adhesion molecule-1 is a regulator of ovarian cancer peritoneal metastasis. Cancer Res. 69(4), 1469-1476 (2009).
59. Yurkovetsky Z, Skates S, Lomakin A et al. Development of a multimarker assay for early detection of ovarian cancer. J. Clin. Oncol. 28(13), 2159-2166 (2010).
60. Scambia G, Testa U, Benedetti Panici P et al. Prognostic significance of interleukin 6 serum levels in patients with ovarian cancer. Br. J. Cancer 71(2), 354-356 (1995).
61. Lokshin AE, Winans M, Landsittel D et al. Circulating IL-8 and anti-IL-8 autoantibody in patients with ovarian cancer. Gynecol. Oncol. 102(2), 244-251 (2006).
62. Edgell T, Martin-Roussety G, Barker G et al. Phase II biomarker trial of a multimarker diagnostic for ovarian cancer. J. Cancer Res. Clin. Oncol. 136(7), 1079-1088 (2010).
63. Hefler LA, Grimm C, Ackermann S et al. An interleukin-6 gene promoter polymorphism influences the biological phenotype of ovarian cancer. Cancer Res. 63(12), 3066-3068 (2003).
64. Tringler B, Liu W, Corral L et al. B7-H4 overexpression in ovarian tumors. Gynecol. Oncol. 100(1), 44-52 (2006).
65. Simon I, Zhuo S, Corral L et al. B7-h4 is a novel membrane-bound protein and a candidate serum and tissue biomarker for ovarian cancer. Cancer Res. 66(3), 1570-1575 (2006).
66. Urieli-Shoval S, Finci-Yeheskel Z, Dishon S et al. Expression of serum amyloid a in human ovarian epithelial tumors: implication for a role in ovarian tumorigenesis. J. Histochem. Cytochem. 58(11), 1015-1023 (2010).
67. Moshkovskii SA, Vlasova MA, Pyatnitskiy MA et al. Acute phase serum amyloid A in ovarian cancer as an important component of proteome diagnostic profiling. Proteomics Clin. Appl. 1(1), 107-117 (2007).
68. Ahmed N, Oliva KT, Barker G et al. Proteomic tracking of serum protein isoforms as screening biomarkers of ovarian cancer. Proteomics 5(17), 4625-4636 (2005).
69. Toyokuni S. Novel aspects of oxidative stressassociated carcinogenesis. Antioxid. Redox Signal. 8(7-8), 1373-1377 (2006).
70. Koshkaryev A, Piroyan A, Torchilin VP. Increased apoptosis in cancer cells in vitro and in vivo by ceramides in transferrin-modified liposomes. Cancer Biol. Ther. 13(1), 50-60 (2012).
71. Su F, Lang J, Kumar A et al. Validation of candidate serum ovarian cancer biomarkers for early detection. Biomark. Insights 2, 369-375 (2007).
72. Kim JH, Skates SJ, Uede T et al. Osteopontin as a potential diagnostic biomarker for ovarian cancer. JAMA 287(13), 1671-1679 (2002).
73. Nakae M, Iwamoto I, Fujino T et al. Preoperative plasma osteopontin level as a biomarker complementary to carbohydrate antigen 125 in predicting ovarian cancer. J. Obstet. Gynaecol. Res. 32(3), 309-314 (2006).
74. Mor G, Visintin I, Lai Y et al. Serum protein markers for early detection of ovarian cancer. Proc. Natl Acad. Sci. USA 102(21), 7677-7682 (2005).
75. Ye B, Skates S, Mok SC et al. Proteomic-based discovery and characterization of glycosylated eosinophil-derived neurotoxin and COOHterminal osteopontin fragments for ovarian cancer in urine. Clin. Cancer Res. 12(2), 432-441 (2006).
76. Borgono CA, Diamandis EP. The emerging roles of human tissue kallikreins in cancer. Nat. Rev. Cancer 4(11), 876-890 (2004).
77. Rosen DG, Wang L, Atkinson JN et al. Potential markers that complement expression of CA125 in epithelial ovarian cancer. Gynecol. Oncol. 99(2), 267-277 (2005).
78. Diamandis EP, Okui A, Mitsui S et al. Human kallikrein 11: a new biomarker of prostate and ovarian carcinoma. Cancer Res. 62(1), 295-300 (2002).
79. Tainsky MA. Genomic and proteomic biomarkers for cancer: a multitude of opportunities. Biochim. Biophys. Acta 1796(2), 176-193 (2009).
80. Donach M, Yu Y, Artioli G et al. Combined use of biomarkers for detection of ovarian cancer in high-risk women. Tumour Biol. 31(3), 209-215 (2010).
81. Kraft A, Weindel K, Ochs A et al. Vascular endothelial growth factor in the sera and effusions of patients with malignant and nonmalignant disease. Cancer 85(1), 178-187 (2009).
82. Harlozinska A, Sedlaczek P, Kulpa J et al. Vascular endothelial growth factor (VEGF) concentration in sera and tumor effusions from patients with ovarian carcinoma. Anticancer Res. 24(2C), 1149-1157 (2004).
83. Li L, Wang L, Zhang W et al. Correlation of serum VEGF levels with clinical stage, therapy efficacy, tumor metastasis and patient survival in ovarian cancer. Anticancer Res. 24(3b), 1973-1979 (2004).
84. Byrne AT, Ross L, Holash J et al. Vascular endothelial growth factor-trap decreases tumor burden, inhibits ascites, and causes dramatic vascular remodeling in an ovarian cancer model. Clin. Cancer Res. 9(15), 5721-5728 (2003).
85. Rice GE, Edgell TA, Autelitano DJ. Evaluation of midkine and anterior gradient 2 in a multimarker panel for the detection of ovarian cancer. J. Exp. Clin. Cancer Res. 29, 62 (2010).
86. Edgell TA, Barraclough DL, Rajic A et al. Increased plasma concentrations of anterior gradient 2 protein are positively associated with ovarian cancer. Clin. Sci. (Lond.) 118(12), 717-725 (2010).
87. Robertson DM, Pruysers E, Jobling T. Inhibin as a diagnostic marker for ovarian cancer. Cancer Lett. 249(1), 14-17 (2007).
88. Tsigkou A, Marrelli D, Reis FM et al. Total inhibin is a potential serum marker for epithelial ovarian cancer. J. Clin. Endocrinol. Metab. 92(7), 2526-2531 (2007).
89. Markova D, Milchev N, Batashki I, Uchikov A. [Role of total inhibin in diagnosis and monitoring of ovarian cancer in postmenopausal women]. Akush. Ginekol. 47(1), 16-19 (2008).
90. Kawamura K, Komohara Y, Takaishi K, Katabuchi H, Takeya M. Detection of M2 macrophages and colony-stimulating factor 1 expression in serous and mucinous ovarian epithelial tumors. Pathol. Int. 59(5), 300-305 (2009).
91. Woo HH, Laszlo CF, Greco S, Chambers SK. Regulation of colony stimulating factor-1 expression and ovarian cancer cell behavior in vitro by miR-128 and miR-152. Mol. Cancer 11(1), 58 (2012).
92. Drapkin R, Clauss A, Skates S. Urokinasetype plasminogen activator receptor: a beacon of malignancy? Clin. Cancer Res. 14(18), 5643-5645 (2008).
93. Hildenbrand R, Gandhari M, Stroebel P, Marx A, Allgayer H, Arens N. The urokinasesystem -role of cell proliferation and apoptosis. Histol. Histopathol. 23(2), 227-236 (2008).
94. Henic E, Borgfeldt C, Christensen IJ, Casslen B, Hoyer-Hansen G. Cleaved forms of the urokinase plasminogen activator receptor in plasma have diagnostic potential and predict postoperative survival in patients with ovarian cancer. Clin. Cancer Res. 14(18), 5785-5793 (2008).
95. Zeineldin R, Muller CY, Stack MS, Hudson LG. Targeting the EGF receptor for ovarian cancer therapy. J. Oncol. 2010, 414676 (2010).
96. Siwak DR, Carey M, Hennessy BT et al. Targeting the epidermal growth factor receptor in epithelial ovarian cancer: current knowledge and future challenges. J. Oncol. 2010, 568938 (2010).
97. Kenny HA, Kaur S, Coussens LM, Lengyel E. The initial steps of ovarian cancer cell metastasis are mediated by MMP-2 cleavage of vitronectin and fibronectin. J. Clin. Invest. 118(4), 1367-1379 (2008).
98. Adley BP, Gleason KJ, Yang XJ, Stack MS. Expression of membrane type 1 matrix metalloproteinase (MMP-14) in epithelial ovarian cancer: high level expression in clear cell carcinoma. Gynecol. Oncol. 112(2), 319-324 (2009).
99. Fishman DA, Liu Y, Ellerbroek SM, Stack MS. Lysophosphatidic acid promotes matrix metalloproteinase (MMP) activation and MMP-dependent invasion in ovarian cancer cells. Cancer Res. 61(7), 3194-3199 (2001).
100. Jeong KJ, Cho KH, Panupinthu N et al. EGFR mediates LPA-induced proteolytic enzyme expression and ovarian cancer invasion: inhibition by resveratrol. Mol. Oncol. (2012).
101. Sedlakova I, Vavrova J, Tosner J, Hanousek L. Lysophosphatidic acid: an ovarian cancer marker. Eur. J. Gynaecol. Oncol. 29(5), 511-514 (2008).
102. Lopez J, Percharde M, Coley HM, Webb A, Crook T. The context and potential of epigenetics in oncology. Br. J. Cancer 100(4), 571-577 (2009).
103. Guo SW, Zilberberg MD, Hummelshoj L. Endometriosis and ovarian cancer. Lancet Oncol. 13(5), e189-190; author reply e190 (2012).
104. Chen H, Hardy TM, Tollefsbol TO. Epigenomics of ovarian cancer and its chemoprevention. Front. Genet. 2, 67 (2011).
105. Creighton CJ, Fountain MD, Yu Z et al. Molecular profiling uncovers a p53-associated role for microRNA-31 in inhibiting the proliferation of serous ovarian carcinomas and other cancers. Cancer Res. 70(5), 1906-1915 (2010).
106. Iorio MV, Visone R, Di Leva G et al. MicroRNA signatures in human ovarian cancer. Cancer Res. 67(18), 8699-8707 (2007).
107. Zhang L, Volinia S, Bonome T et al. Genomic and epigenetic alterations deregulate microRNA expression in human epithelial ovarian cancer. Proc. Natl Acad. Sci. USA 105(19), 7004-7009 (2008).
108. Bartels CL, Tsongalis GJ. MicroRNAs: novel biomarkers for human cancer. Clin. Chem. 55(4), 623-631 (2009).
109. Soto-Reyes E, Gonzalez-Barrios R, Cisneros-Soberanis F et al. Disruption of CTCF at the miR-125b1 locus in gynecological cancers. BMC Cancer 12, 40 (2012).
110. Integrated genomic analyses of ovarian carcinoma. Nature 474(7353), 609-615 (2011).
111. Resnick KE, Alder H, Hagan JP, Richardson DL, Croce CM, Cohn DE. The detection of differentially expressed microRNAs from the serum of ovarian cancer patients using a novel real-time PCR platform. Gynecol. Oncol. 112(1), 55-59 (2009).
112. Chang H, Zhou X, Wang ZN et al. Increased expression of miR-148b in ovarian carcinoma and its clinical significance. Mol. Med. Rep. 5(5), 1277-1280 (2012).
113. Chen X, Ba Y, Ma L et al. Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res. 18(10), 997-1006 (2008).
114. Kuhlmann JD, Rasch J, Wimberger P, Kasimir-Bauer S. microRNA and the pathogenesis of ovarian cancer -a new horizon for molecular diagnostics and treatment? Clin. Chem. Lab. Med. 50(4), 601-615 (2012).
115. Kiehntopf M, Siegmund R, Deufel T. Use of SELDI-TOF mass spectrometry for identification of new biomarkers: potential and limitations. Clin. Chem. Lab. Med. 45(11), 1435-1449 (2007).
116. Wang LN, Tong SW, Hu HD et al. Quantitative proteome analysis of ovarian cancer tissues using a iTRAQ approach. J. Cell. Biochem. 113(12), 3762-3772 (2012).
117. Chon HS, Lancaster JM. Microarray-based gene expression studies in ovarian cancer. Cancer Control 18(1), 8-15 (2011).
118. Shvartsman HS, Lu KH, Lee J et al. Overexpression of kallikrein 10 in epithelial ovarian carcinomas. Gynecol. Oncol. 90(1), 44-50 (2003).
119. Thomson JM, Parker JS, Hammond SM. Microarray analysis of miRNA gene expression. Methods Enzymol. 427, 107-122 (2007).
120. Muralidharan-Chari V, Clancy JW, Sedgwick A, D'souza-Schorey C. Microvesicles: mediators of extracellular communication during cancer progression. J. Cell Sci. 123(Pt 10), 1603-1611 (2010).
121. Hu G, Drescher KM, Chen XM. Exosomal miRNAs: biological properties and therapeutic potential. Front. Genet. 3, 56 (2012).
122. Kharaziha P, Ceder S, Li Q, Panaretakis T. Tumor cell-derived exosomes: a message in a bottle. Biochim. Biophys. Acta 1826(1), 103-111 (2012).
123. Gercel-Taylor C, Atay S, Tullis RH, Kesimer M, Taylor DD. Nanoparticle analysis of circulating cell-derived vesicles in ovarian cancer patients. Anal. Biochem. 428(1), 44-53 (2012).
124. Taylor DD, Gercel-Taylor C. MicroRNA signatures of tumor-derived exosomes as diagnostic biomarkers of ovarian cancer. Gynecol. Oncol. 110(1), 13-21 (2008).
125. Gorelik E, Landsittel DP, Marrangoni AM et al. Multiplexed immunobead-based cytokine profiling for early detection of ovarian cancer. Cancer Epidemiol. Biomarkers Prev. 14(4), 981-987 (2005).
126. Zhang Z, Yu Y, Xu F et al. Combining multiple serum tumor markers improves detection of stage I epithelial ovarian cancer. Gynecol. Oncol. 107(3), 526-531 (2007).
127. Anderson GL, Mcintosh M, Wu L et al. Assessing lead time of selected ovarian cancer biomarkers: a nested case-control study. J. Natl Cancer Inst. 102(1), 26-38 (2010).
128. Fung ET. A recipe for proteomics diagnostic test development: the OVA1 test, from biomarker discovery to FDA clearance. Clin. Chem. 56(2), 327-329 (2010).
129. Ware Miller R, Smith A, Desimone CP et al. Performance of the American College of Obstetricians and Gynecologists' ovarian tumor referral guidelines with a multivariate index assay. Obstet. Gynecol. 117(6), 1298-1306 (2011). Websites
130. Yale Cancer Center. Genetics of Breast and Ovarian Cancer (PDQ®). http://medicine.yale.edu/cancer/patient/programs/breast/info/info.aspx?id= cdr62855
131. National Cancer Institute. Genetics of Breast and Ovarian Cancer (PDQ®). www.cancer.gov/cancertopics/pdq/genetics/breast-and-ovarian/ HealthProfessional/page1
132. Network NCC. Genetic/Familial High Risk Assessment: Breast and Ovarian 2012. www.nccn.org/professionals/physician-gls/pdf/genetics-screening.pdf
133. The Cancer Genome Atlas Project, NIH. www.cancer.gov/aboutnci/recovery/ recoveryfunding/tcga